A

Abbott India Ltd
NSE:ABBOTINDIA

Watchlist Manager
Abbott India Ltd
NSE:ABBOTINDIA
Watchlist
Price: 28 513.3 INR -0.16% Market Closed
Market Cap: 605.9B INR
Have any thoughts about
Abbott India Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one ABBOTINDIA stock under the Base Case scenario is 25 760.19 INR. Compared to the current market price of 28 513.3 INR, Abbott India Ltd is Overvalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ABBOTINDIA Relative Value
Base Case
25 760.19 INR
Overvaluation 10%
Relative Value
Price
A
Worst Case
Base Case
Best Case

Valuation Multiples

10
P/S
P/S
Price to Sales
10
vs History
25
vs Industry
14
Median 3Y
9
Median 5Y
8.4
Industry
2.5
Forward
9.1
More Details
47.2
P/E
P/E
Price to Earnings
47.2
vs History
80
vs Industry
9
Median 3Y
49
Median 5Y
49
Industry
21.8
Forward
44.5
More Details
59.9
P/OCF
P/OCF
Price to OCF
59.9
vs History
3
vs Industry
8
Median 3Y
48.2
Median 5Y
48.6
Industry
16.1
More Details
66.5
P/FCFE
P/FCFE
Price to FCFE
66.5
vs History
4
vs Industry
11
Median 3Y
52.7
Median 5Y
54.2
Industry
23.8
More Details
16.4
P/B
P/B
Price to Book Value
16.4
vs History
24
vs Industry
4
Median 3Y
15.8
Median 5Y
15.1
Industry
2.1
More Details
9.7
EV/S
EV/S
Enterprise Value to Sales
9.7
vs History
25
vs Industry
14
Median 3Y
9
Median 5Y
8
Industry
2.7
Forward
8.8
More Details
21.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
21.4
vs History
27
vs Industry
8
Median 3Y
20
Median 5Y
17.6
Industry
5.2
More Details
37.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
37.9
vs History
53
vs Industry
8
Median 3Y
38.3
Median 5Y
37.5
Industry
13.5
Forward
35
More Details
39.7
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
39.7
vs History
54
vs Industry
9
Median 3Y
40.5
Median 5Y
39.8
Industry
16.8
Forward
35.1
More Details
58
EV/OCF
EV/OCF
Enterprise Value to OCF
58
vs History
4
vs Industry
9
Median 3Y
46.5
Median 5Y
46.5
Industry
15.2
More Details
60.7
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
60.7
vs History
4
vs Industry
9
Median 3Y
48.4
Median 5Y
48.5
Industry
19.3
More Details
26.8
EV/IC
EV/IC
Enterprise Value to IC
26.8
vs History
82
vs Industry
4
Median 3Y
28.9
Median 5Y
38
Industry
1.9
More Details

Multiples Across Competitors

ABBOTINDIA Competitors Multiples
Abbott India Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Abbott India Ltd
NSE:ABBOTINDIA
605.9B INR 10 47.2 37.9 39.7
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
756.2B USD 18.5 90.3 48.5 54.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK 10.2 29 20.2 23
US
Johnson & Johnson
NYSE:JNJ
350.6B USD 4 23.9 11.6 15
US
Merck & Co Inc
NYSE:MRK
252B USD 4 20.7 10.5 12.6
CH
Roche Holding AG
SIX:ROG
200.1B CHF 3.4 17.4 9.8 11.6
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP 4.1 31.5 169.4 253.8
CH
Novartis AG
SIX:NOVN
171.5B CHF 3.8 10.8 9.4 13.1
US
Pfizer Inc
NYSE:PFE
151.5B USD 2.5 35.6 10.6 16
P/S Multiple
Revenue Growth P/S to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average P/S: 382 942.9
10
40%
0.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
18.5
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
10.2
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
4
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average P/E: 34.1
47.2
37%
1.3
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
90.3
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
29
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.9
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.7
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.4
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31.5
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.6
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average EV/EBITDA: 417.4
37.9
46%
0.8
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48.5
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
20.2
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.6
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.5
331%
0
CH
Roche Holding AG
SIX:ROG
9.8
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.4
64%
2.7
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.6
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
A
Abbott India Ltd
NSE:ABBOTINDIA
Average EV/EBIT: 1 814.1
39.7
47%
0.8
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.2
211%
0.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
23
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
15
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.6
675%
0
CH
Roche Holding AG
SIX:ROG
11.6
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.8
131%
1.9
CH
Novartis AG
SIX:NOVN
13.1
58%
0.2
US
Pfizer Inc
NYSE:PFE
16
68%
0.2

See Also

Summary
ABBOTINDIA intrinsic value, competitors valuation, and company profile.
DCF Valuation
ABBOTINDIA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ABBOTINDIA stock valuation using valuation multiples.
Wall Street Estimates
ABBOTINDIA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ABBOTINDIA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 210,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.